DecOmPress
Financiado
Decoding spatio temporal omics in progressive neuroinflammation
Multiple sclerosis (MS) is a paradigmatic progressive neuroinflammatory disease characterized by multiple lesions across the entire central nervous system including both gray and white matter areas. Deconvoluting the spatio-tempor...
Multiple sclerosis (MS) is a paradigmatic progressive neuroinflammatory disease characterized by multiple lesions across the entire central nervous system including both gray and white matter areas. Deconvoluting the spatio-temporal cellular and molecular landscape is therefore key to understanding underlying disease mechanisms and to develop cell-type specific therapies. The DecOmPress proposal is about integrative human and mouse single-cell genomic strategies to track-down reactive cellular states in compartmentalized progressive neuroinflammation. DecOmPress has two major research tracks (RTs).
RT1 is an MS tissue discovery pipeline utilizing single-nucleus RNA and open chromatin sequencing. RT1 is about developing novel integrative computational tools to process sequencing data from different anatomical lesion areas implementing a large multiplex single-nucleus genomic dataset from the anterior visual system. RT1 is also about decoding compartmentalized inflammation in meningeal versus perivascular tissue niches.
RT2 is a functional validation pipeline utilizing complex transgenic and disease mouse models as well as human organoids in combination with single-cell physiology and genomics. RT2 is about dissecting glial-intrinsic mechanisms at the chronically inflamed white matter lesion rim focusing on MS-specific oligodendrocyte and microglia subtypes. RT2 is also about decoding neuron subtype specific pathologies focusing on projection neurons and the contribution of local (meningeal) and distant (white matter tracts) inflammation and demyelination to cell-type specific neurodegeneration.
In summary, DecOmPress is a highly innovative and fully translational multidisciplinary proposal aiming at identifying novel cell-type specific disease mechanisms and therapeutic targets.
ver más
Duración del proyecto: 62 meses
Fecha Inicio: 2020-10-29
Fecha Fin: 2025-12-31
Fecha Fin: 2025-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-10-29
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-STG:
ERC STARTING GRANTS
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
RUPRECHTKARLSUNIVERSITAET HEIDELBERG
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
662.08K€ |
Participante